Latest Information
November 16, 2016
Among patients with intermediate- or poor-risk metastatic renal cell carcinoma (mRCC), first-line therapy with cabozantinib was superior to standard-of-care sunitinib with respect to objective response rate and progression-free survival, according to a study published in the Journal of Clinical Oncology
October 14th, 2016
Patients with aggressive forms of metastatic renal cell carcinoma (RCC) benefited more from treatment with cabozantinib (Cometriq) than with sunitinib (Sutent), according to a study reported here.
September 7th, 2016
Obesity is a risk factor for kidney cancer. Yet, obese people with advanced kidney cancer seem to live longer than normal-weight or underweight patients, a new study finds.
Print this page Tell A Friend Add to Favorites

Dr. Kevin Zbuk

B.Sc. (Alberta), MD (Alberta), FRCPC


Assistant Professor, McMaster University
Department of Oncology - Division of Medical Oncology




Office:

Juravinski Cancer Centre
3rd Floor
699 Concession Street
Hamilton Ontario, L8V 5C2

Contact Information:
P: 905-387-9711 Ext. 64602
F: 905-575-6326
E:kevin.zbuk@jcc.hhsc.ca

Support Staff:
Karen Chadwick (Administrative Assistant)
P: 905-387-9711 Ext. 64602
F: 905-575-6326
E: Karen.Chadwick@jcc.hhsc.ca

Areas of Interest

Dr. Zbuk's areas of interest include cancer genetics and the molecular classification of gastrointestinal polyposis syndromes. Dr. Zbuk's oncology practice focuses on gastrointestinal malignancies.

Selected Publications

Zbuk K and Eng C “Cancer Phenomics: RET and PTEN as illustrative models”. Nature Reviews Cancer. 2007 Jan;7(1):35-45.

Ni Y*, Zbuk K*, Sadler T, et. al. « Germline mutations and variants in the succinate dehydrogenase genes in Cowden andCowden-like syndromes” American Journal of Human Genetics 2008 (in press)

Plon, S.E., Pirics, M.L., Agrawal, S., Zbuk, K., Nuchtern, J., Hicks, J., Hegde, M., Lip-Hon Chin, E., Eng, C., and H. Russell (2008). Multiple Tumors in a Child with Germline Mutations in TP53 and PTEN. New England J of Medicine, in press.

* joint first authors